PressMay 2, 2023 Blackhawk and Mindbio Therapeutics Corp. (formerly, 1286409 B.C. LTD.) Announce Completion of Plan of Arrangement
PressMay 2, 2023 Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
PressMay 2, 2023 PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
PressMay 2, 2023 Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
PressMay 2, 2023 Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
PressApril 28, 2023 atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
PressApril 27, 2023 PSYC Explores the Boundaries of Psychedelics and Society with New Video Series, “PSYC Taboo”
PressApril 27, 2023 Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
PressApril 26, 2023 Mindbloom Announces Partnership with SHIFT To Offer Affordable At-Home Ketamine Therapy To Its Employees
PressApril 26, 2023 Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease With a Proprietary formulation Based On 5-MeO-DMT
PressApril 26, 2023 Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
PressApril 26, 2023 Moon Equity Holdings to Sell BitGift Asset to Silo Wellness in Exchange for a Dividend
PressApril 25, 2023 Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare Investor Conference
PressApril 25, 2023 BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
PressApril 24, 2023 Apex Labs Granted Approval for 160 Patient Macrodose Multi-Dose Psilocybin Clinical Trial by Health Canada
PressApril 24, 2023 Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
